Award NoticeAwarded

Development Of a Concentrated Tranexamic Acid (TXA) Intramuscular Injection

HEALTH AND HUMAN SERVICES, DEPARTMENT OF · BARDA - ASPR / DAAPPO / BARDA DCMA

This notice records an award. Find active opportunities

Award Information

HEALTH AND HUMAN SERVICES, DEPARTMENT OF awarded this contract to RAFA LABORATORIES LTD Jerusalem ISR for $186,004,780 on September 30, 2025, as part of federal procurement initiatives.

This award is part of federal acquisition procurement activities.

Award Number: 75A50125C00018
Award Amount: $186,004,780
Award Date: September 30, 2025
Awardee: RAFA LABORATORIES LTD Jerusalem ISR

View full award details on USASpending.gov

Contract Details

Notice ID: 75A50125C00018
Opportunity Type: Award Notice
Agency: HEALTH AND HUMAN SERVICES, DEPARTMENT OF
Sub-Agency: OFFICE OF ASSISTANT SECRETARY FOR PREPAREDNESS AND RESPONSE
Office: BARDA - ASPR / DAAPPO / BARDA DCMA
Posted Date: Wednesday, October 1, 2025
Response Deadline: Not specified
NAICS Code: 541714 - Research and Development in Biotechnology (except Nanobiotechnology)
PSC Code: AN13
Set-Aside: Full & Open Competition
Place of Performance: Jerusalem, IL-JM, ISR
Status: Awarded

View on SAM.gov

Description

This award is for the development of a concentrated Tranexamic Acid (TXA) Intramuscular Injection. The Government seeks this development in order to receive FDA approval for the concentrated IM TXA formulation that can be delivered in a pref-filled syringe or a dedicated autoinjector. This contract action was awarded competitively as a Cost Share Contract. A Cost Share Contract was used in accordance with FAR 35.006 (c) due to an absence of precise specifications and difficulties in estimating costs with accuracy.